Merrill makes additions to EMEA equity-linked group

Tobias Gehrke, Andrew Song, Daniel Cangemi, Geir Espeskog, Matt Renirie and Michael Ebert have all joined Merrill from Goldman Sachs. Gehrke leads the institutional derivatives sales effort to UK, Scandinavian and Benelux clients, while Espeskog focuses on selling derivatives to Scandinavian and Benelux customers. Song heads the index vanilla trading desk, with Ebert focusing on trading Eurostoxx50 options while Cangemi focuses on trading exotics, a desk headed by Matthew Porter.

Renirie’s focus is on hedge funds, primarily volatility arbitrage clients. Also working on hedge funds are Mike Ward, from Lehman Brothers, who will deal primarily with long/short hedge sales, and Andreas Konomis, previously at Prime Financial Services.

Tobias Hupfauer, Gene Linetsky and Elias Jaeggi join from UBS. Hupfauer sells derivatives to German and Austrian institutions, and is joined in this role by Alex Trojanow, previously at Royal Bank of Canada. Jaeggi joins as a warrants trader, under Michael Hull.

Linetsky focuses on structured equity products in emerging European regions. In addition, Donald Leitch joins the bank to head the structuring and operation desk, focusing on expanding the product range in exotic equity and fund derivatives markets, from Commerzbank. Also focusing on structured products are Evran Mersin, marketing structured solutions to northern and emerging European retail institutions, who arrives from Credit Suisse First Boston, and Marco Stauffacher, selling structured products to Swiss institutions, joining from Lehman Brothers.

Gwenael Fort joins Merrill Lynch from Dresdner Kleinwort Wasserstein to trade European convertible bonds, while from Banco Santander, Ethel Chicharro Sanchez arrives in a derivatives sales role.

  • LinkedIn  
  • Save this article
  • Print this page  

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: